As shown in Supplementary Fig. 1a, EGF-induced EGFR degradation was blocked by either a proteasome inhibitor (MG132) or a lysosome inhibitor (chloroquine, CLQ) in NSCLC H1299 (wild-type EGFR) or H1975 (EGFRL858R/T790M) cells. Here, EGF is linked to non-small cell lung carcinoma.